综上所述，TCR-T细胞治疗作为一种新兴的免疫疗法，在实体瘤的治疗中展现出巨大的潜力和前景。随着相关技术的不断发展和完善，我们有理由相信，TCR-T细胞治疗将在未来的医学领域中发挥更加重要的作用，为肿瘤患者带来更加有效的治疗方案。【参考文献】1. Lijun Zhao and Yu Cao. "Engineered T Cell Therapy for Ca...
“TCR-T疗法”全称为“T细胞受体工程化T细胞疗法(T-cell receptor engineered T cell therapy,TCR-T)”,是利用基因工程技术,将TCR基因序列转移到T细胞中,相当于在T细胞上安装了一个“精密的感知器”,改造后的T细胞可以特异性识别肿瘤抗原,能快速...
参考资料: [1] Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor. Retrieved August 1, 2024, from https://www.adaptimmune.com/investors-and-media/n...
TCR-T(T cell receptor engineered T cell therapy)指的是 T 细胞受体工程化 T 细胞疗法,此技术主要通过基因编辑,将能够特异性识别肿瘤抗原的 TCR 基因导入T细胞中,随后在体外扩增并输注到患者体内以杀死肿瘤细胞[2]。TCR-T 疗法依赖 MHC 分子呈递肿瘤抗原,并且能够有效识别潜在的胞内抗原,这使得 TCR-T 疗法的...
TCR-T TCR-T(T cell receptor engineered T cell therapy)指的是 T 细胞受体工程化 T 细胞疗法,此技术主要通过基因编辑,将能够特异性识别肿瘤抗原的 TCR 基因导入T细胞中,随后在体外扩增并输注到患者体内以杀死肿瘤细胞[2]。TCR-T 疗法依赖 MHC 分子呈递肿瘤抗原,并且能够有效识别潜在的胞内抗原,这使得 TCR-...
研发公司:星汉德(SCG Cell Therapy)适应证:乙肝病毒相关实体瘤(包括宫颈癌、口咽癌、头颈癌、阴道癌、外阴癌、阴茎癌等)药物介绍 SCG142是一款新型人乳头瘤病毒(HPV)E7特异性T细胞受体工程化T(TCR-T)细胞疗法。其独特之处在于为T细胞配备嵌合开关受体，可突破恶劣的肿瘤微环境，将抑制信号转化为共刺激信号，激活...
[3]Thomas S S,et al.Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors[J].2024.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2542 [4]Zhao X,et al.The ...
Comparing CAR and TCR engineered T cell performance as a function of tumorcell exposure. Oncoimmunology. 2022, 11(1):2033528.[3] Baulu E, Gardet C, Chuvin N, et al.TCR-engineered T cell therapy in solid tumors: State of the art andperspectives. Sci Adv. 2023, 9(7):eadf3700.
and clinical application of tumor-specific neoantigens for TCR-T cells.” Molecular cancer vol. 22,1 141. 30 Aug. 2023.[2] Baulu, Estelle et al. “TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.” Science advances vol. 9,7 (2023): eadf3700.
[1] Shafer P, Kelly LM, Hoyos V. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front Immunol. 2022;13:835762.[2] Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. ...